Eli Lilly breaks ground on a $3.5 billion injectables plant in Pennsylvania's Lehigh Valley

ConstruBIM Editorial November 21, 2026 2 min read 2 sources checked

Eli Lilly broke ground on 12 November 2026 on a $3.5 billion plant in Fogelsville, Pennsylvania, for injectable medicines including the investigational obesity drug retatrutide. The site is due to open in 2031 and create 850 permanent jobs.

Westbound Old Route 22 (Main Street) in Fogelsville, Pennsylvania, the village beside the Lehigh Valley site
Image: Mr. Matté, CC BY-SA 4.0, Wikimedia Commons

Eli Lilly broke ground on Thursday, 12 November 2026, on a $3.5 billion manufacturing facility in Fogelsville, Pennsylvania, in the Lehigh Valley. The plant will make injectable medicines and devices, including retatrutide, the company's investigational once-weekly triple hormone receptor agonist that targets the GIP, GLP-1 and glucagon receptors.

The brief

Lilly expects the facility to be operational by 2031 and to create 850 permanent, high-wage jobs. The company says it is currently hiring in the Lehigh Valley. The project was first announced earlier in 2026, and it is one of four new US sites that Lilly is building for injectable medicines and devices.

Where it fits

The Fogelsville plant is part of Lilly's $50 billion push to expand medicine production in the United States. Retatrutide is still investigational and has not been approved for sale, so the factory is being built ahead of any marketing decision. That sequencing is a planning choice the company has made publicly.

Why it matters for delivery teams

A sterile injectables plant is a dense building. Clean rooms, process piping, utility loops and validation documentation all have to be coordinated before the first batch can run. Teams working on similar sites should watch how the schedule to 2031 is sequenced against validation, and they should keep one shared model and one record of equipment data from design through commissioning.

Image: Westbound Old Route 22 (Main Street) in Fogelsville, the village where the plant is being built; the photograph shows the town, not the construction site. Photo: Mr. Matté, CC BY-SA 4.0, via Wikimedia Commons.

Sources checked for this story

  1. Eli Lilly breaks ground on $3.5B Pennsylvania site for next-generation obesity medicines — Pharma Manufacturing, November 13, 2026
  2. PA: Lilly Breaks Ground on $3.5B Lehigh Valley Site to Make Next-Generation Obesity Medicines — Trade & Industry Development, November 16, 2026
Pharma constructionLehigh ValleyManufacturingMegaprojectPennsylvania
More stories
All news →

Need this done, not just read about?

Describe your scope and our quote engine returns cost, team size and timeline live.

Get an instant quote